Abbreviation
Recombinant Human PDGFRA protein, partial (Active)
Purity
Greater than 95% as determined by SDS-PAGE.
Greater than 95% as determined by SEC-HPLC.
Endotoxin
Less than 1.0 EU/ug as determined by LAL method.
Activity
Measured by its binding ability in a functional ELISA. Immobilized Human PDGFRA at 2 μg/mL can bind Anti-PDGFRA recombinant antibody (CSB-RA017712MA1HU). The EC50 is 0.6497-0.8371 ng/mL.
Alternative Names
Platelet-derived growth factor receptor alpha; EC:2.7.10.1; PDGF-R-alpha; PDGFR-alpha; Alpha platelet-derived growth factor receptor; Alpha-type platelet-derived growth factor receptor; CD140 antigen-like family member A; CD140a antigen; Platelet-derived growth factor alpha receptor; Platelet-derived growth factor receptor 2 (PDGFR-2); CD140a; PDGFRA; PDGFR2, RHEPDGFRA
Species
Homo sapiens (Human)
Expression Region
24-528aa
Target Protein Sequence
QLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYPMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVPLGMTDYLVIVEDDDSAIIPCRTTDPETPVTLHNSEGVVPASYDSRQGFNGTFTVGPYICEATVKGKKFQTIPFNVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNNEVVDLQWTYPGEVKGKGITMLEEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENLTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDLVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRDRSTVEGRVTFAKVEETIAVRCLAKNLLGAENRELKLVAPTLRSELTVA
Note: The complete
sequence may include tag sequence, target protein sequence, linker sequence and extra sequence that is
translated with the protein sequence for the purpose(s) of secretion, stability, solubility, etc.
If the exact amino acid sequence of this recombinant protein is critical to your application,
please explicitly request the full and complete sequence of this protein before ordering.
Tag Info
C-terminal 10xHis-tagged
The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.
Form
Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer
Lyophilized from a 0.2 μm sterile filtered PBS, 6% Trehalose, pH 7.4
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Storage Condition
Store at -20°C/-81°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Lead Time
3-7 business days
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4℃ for up to one week.
Shelf Life
The shelf life is related to many factors, storage state, storage temperature and the stability of the product itself. Generally, the shelf life of lyophilized form is 6 months at -20°C/-80°C from the date of receipt.
Datasheet & COA
Please contact us to get it.
Images
-
(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
-
Activity
Measured by its binding ability in a functional ELISA. Immobilized Human PDGFRA at 2 μg/ml can bind Anti-PDGFRA recombinant antibody (CSB-RA017712MA1HU). The EC50 is 0.6497-0.8371 ng/mL.
-
The purity of PDGFRA was greater than 95% as determined by SEC-HPLC
Description
PDGFRA mediates critical signaling in vascular development and tissue repair, making its extracellular domain a key target for therapeutic antibody development and small-molecule inhibitor screening. This mammalian-expressed construct spanning residues 24–528 captures the complete ligand-binding region and demonstrates quantifiable antibody-binding activity with an EC50 of 0.65–0.84 ng/mL in functional ELISA, providing a validated basis for competitive inhibition assays, blocking antibody screening, and epitope mapping studies. The dual-method purity assessment—exceeding 95% by both SDS-PAGE and SEC-HPLC—combined with endotoxin levels below 1.0 EU/μg, satisfies the quality criteria typical for surface plasmon resonance and biolayer interferometry experiments where conformational integrity directly impacts affinity measurements. Researchers conducting ligand-receptor interaction studies or characterizing anti-PDGFRA therapeutic candidates will find this construct supports reproducible binding kinetics determination and serves as a reliable positive control in receptor-ligand interaction platforms.
